Tan, Lavinia
Brown, Chris http://orcid.org/0000-0003-2506-4871
Mersiades, Antony
Lee, Chee Khoon
John, Thomas http://orcid.org/0000-0003-3399-5342
Kao, Steven
Newnham, Genni
O’Byrne, Kenneth
Parakh, Sagun
Bray, Victoria
Jasas, Kevin
Yip, Sonia
Wong, Stephen Q.
Ftouni, Sarah
Guinto, Jerick
Chandrashekar, Sushma
Clarke, Stephen
Pavlakis, Nick
Stockler, Martin R.
Dawson, Sarah-Jane http://orcid.org/0000-0002-8276-0374
Solomon, Benjamin J. http://orcid.org/0000-0003-3059-5730
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1158345)
AstraZeneca Australia
Article History
Received: 6 July 2023
Accepted: 7 February 2024
First Online: 28 February 2024
Competing interests
: L. Tan reports receiving speaker fees from Roche. C.K. Lee reports grants from AstraZeneca, Roche, Amgen, Merck KGA and honorarium from AstraZeneca, Amgen, GSK, Merck KGA, Novartis, Pfizer, Roche, and Takeda. He reports receiving travel fees from AstraZeneca. T. John reports receiving honorarium and is an advisory board member for BMS, AstraZeneca, Amgen, Roche, Pfizer, Takeda, Boehringer Ingelheim, MSD, Merck, Puma, Specialised Therapeutics, and Gilead. He reports receiving travel/speaker fees from AstraZeneca and MSD. S. Kao serves on advisory boards for AstraZeneca, Pfizer, Roche, BMS, MSD, and Takeda. He reports receiving honorarium to institution for MSD, BMS, Roche, AstraZeneca, Pfizer, Boeringher Ingelheim and travel support from BMS, Roche, AstraZeneca, and Boeringher Ingelheim. K. O’Byrne reports receiving honorarium from Merck Sharp & Dohme, BMS, Roche, Boehringer Ingelheim, AstraZeneca, Pfizer/EMD Serano, Novartis, Janssen-Cilag, Yuhan, Tristar Technology Group, Takeda, Amgen, BeiGene. He has consulting/advisory role for Merck Sharp & Dohme, Boehringer Ingelheim, Roche/Genentech, Janssen-Cilag, Pfizer, AstraZeneca/MedImmune, BMS, Novartis, Yuhan, Sanofi, Amgen, BeiGene. He has stock and other ownership interests with Carpe Vitae Pharmaceuticals, Replica Pharmaceuticals, DGC diagnostics and has four active patents (two published and two provisional). He also has speaking roles for Merck Sharp & Dohme, Boehringer Ingelheim, BMS, Roche, Janssen. S. Parakh reports receiving research funding from Bayer and Roche, honorarium from BMS and Roche. He is an advisory board member for AstraZeneca and MSD. S. Q. Wong reports receiving speaker fees from Roche. S. Clarke is an advisory board member for AstraZeneca and Beigene and has speaking roles for AstraZeneca. N. Pavlakis reports consulting or advisory role for Roche, Boehringer Ingelheim, AstraZeneca, Merck KGA, Merck Serono, Amgen, Merck Sharp & Dohme, Novartis, Pfizer, Takeda, and BMS. M.R. Stockler reports receiving research funding from Astellas, Celgene, Bayer, Bionomics, Medivation, Sanofi, Pfizer, AstraZeneca, BMS, Roche, Amgen, Merck Sharp & Dohme, Tilray, and BeiGene. He has speaking roles for Astellas Pharma and Medivation/Pfizer. SJ. Dawson has received research funding from Cancer Therapeutics CRC (CTx) and Genentech. She has been an advisory board member for AstraZeneca, Inivata and Adela. B. J. Solomon reports receiving honorarium and is an advisory board member for AstraZeneca, Pfizer, Novartis, Roche, Eli Lilly, Amgen, Merck, Bristol Myers Squibb, Takeda, Janssen, and BeiGene. No potential conflicts of interest were disclosed by the other authors.